Holdings
Eaton Vance Worldwide Health Sciences Fund
As of May 31, 2026, Eaton Vance Worldwide Health Sciences Fund reported 41 positions worth US$753M. Largest: Eli Lilly And Company, Abbvie Inc. and Johnson & Johnson. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Eli Lilly And Company | 85,543 | US$94.5M | −6,863 | May 31, 2026 |
| Abbvie Inc. | 225K | US$48.9M | −21,559 | May 31, 2026 |
| Johnson & Johnson | 217K | US$48.9M | no change | May 31, 2026 |
| Astrazeneca Plc | 255K | US$47.3M | −11,968 | May 31, 2026 |
| Unitedhealth Group Incorporated | 109K | US$41.6M | no change | May 31, 2026 |
| Roche Holding Ltd | 98,026 | US$41.2M | −27,800 | May 31, 2026 |
| Merck & Company, Inc. | 324K | US$38.5M | +16,988 | May 31, 2026 |
| Bristol-myers Squibb Company | 564K | US$32.2M | no change | May 31, 2026 |
| Vertex Pharmaceuticals Incorporated | 57,284 | US$25.6M | −3,396 | May 31, 2026 |
| Gilead Sciences, Inc. | 188K | US$25.3M | no change | May 31, 2026 |